

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

**Evaluation of long-term sequelae by cardiopulmonary exercise testing
12 months after hospitalization for critical COVID-19**

Sofia Noureddine^{1*}, Pauline Roux-Claudé^{1*}, Lucie Laurent¹, Ophélie Ritter¹, Pauline Dolla¹,
Sinan Karaer¹, Frédéric Claudé¹, Guillaume Eberst^{1,2}, Virginie Westeel^{1,2}, Cindy Barnig^{1,3}

¹ Department of Chest Disease, University Hospital Besançon, France

² Methodology and Quality of Life in Oncology Unit, University Hospital, Besançon, France
and UMR 1098, University of Franche-Comté, Besançon, France

³ University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions
Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, F-25000
Besançon, France

*Shared co-first authorship

Address correspondence to:

Cindy Barnig

Department of Chest Disease,

University Hospital Besançon,

F-25000 Besançon, France

Tel: +33 3 81 66 88 02

e-mail : cindy.barnig@univ-fcomte.fr

28 **Abstract**

29 **Background:** Cardiopulmonary exercise testing (CPET) is an important clinical tool that
30 provides a global assessment of the respiratory, circulatory and metabolic responses to
31 exercise which are not adequately reflected through the measurement of individual organ
32 system function at rest. In the context of critical COVID-19, CPET is an ideal approach for
33 assessing long term sequelae.

34 **Methods:** In this prospective single-center study, we performed CPET in 60 patients, 12
35 months after a critical COVID-19 infection that required intensive care unit (ICU) treatment.
36 Lung function at rest and chest computed tomography (CT) scan were also performed.

37 **Results:** Twelve months after severe COVID-19 pneumonia, the majority of the patients
38 had a peak O_2 uptake ($V'O_2$) considered within normal limits. However, length of ICU stay
39 remained an independent predictor of $V'O_2$. Surprisingly, more than half of the patients
40 with a normal peak predicted $V'O_2$ showed ventilatory inefficiency during exercise (high
41 VE/VCO_2 ratio and high VE/VCO_2 slope) with increased physiological dead space (VD/Vt)
42 and low end-tidal CO_2 partial pressure ($PETCO_2$) values. This impairment was even more
43 pronounced in patients with persistent dyspnea. Notably, peak VD/Vt values were
44 positively correlated with peak D-Dimer plasma concentrations from blood samples
45 collected during ICU stay.

46 **Conclusions:** Even if reduced exercise capacity was rare 12 months after critical COVID-
47 19, more than half of the patients with normal exercise capacity showed ventilatory
48 inefficiency.

49

50

51

52 **Background**

53 In December 2019, Wuhan city identified a new type of coronavirus, named severe
54 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that rapidly spread all over the
55 world and caused an immense global health crisis. Most patients presented mild to
56 moderate respiratory disease, experiencing cough, fever, headache, myalgia, diarrhea and
57 anosmia. However, around 3–20% of people with SARS-CoV-2 required hospitalization
58 and a considerable subset needed intensive care because of respiratory failure with
59 severe hypoxemia and bilateral radiographic opacities [1].

60 Studies found that most SARS-CoV-2 survivors, even those who were critically ill
61 during hospital stay, have normal pulmonary function tests within 12 months after
62 symptom onset [2]. Nevertheless, more than half of the patients who recover from
63 Coronavirus disease 2019 (COVID-19) complain of long-term persistent dyspnea [3].

64 Cardiopulmonary exercise testing (CPET) is an important clinical tool that provides
65 a global assessment of the respiratory, circulatory and metabolic responses to exercise
66 which are not adequately reflected through the measurement of individual organ system
67 function at rest [4]. In the context of COVID-19, CPET is an ideal approach for unmasking
68 functional anomalies and long term sequelae. To date, only a few studies have
69 investigated the exercise capacity in patients who have recovered from COVID-19.
70 Assessment in the short-term post-COVID period revealed mostly a mild decrease in peak
71 O_2 uptake ($V'O_2$) and a low anaerobic threshold, without cardiac impairment or ventilatory
72 limitation, suggestive of physical deconditioning [5, 6]. However, there is currently limited
73 data on long term functional capacities in patients after COVID-19, especially after critical
74 infection.

75 The aim of our study was to evaluate cardiopulmonary exercise capacities in a
76 prospective cohort of patients that required critical care management during the first wave

77 of COVID-19, 12 months after symptom onset.

78 **Methods**

79 ***Study design and subjects***

80 This was a prospective single-center observational cohort study. All patients who
81 were admitted between April to June 2020 to any of the intensive care units (ICU) of the
82 University Hospital of Besançon (France) for a COVID-19 infection were contacted upon
83 hospital discharge and invited to participate in the trial. Patients were eligible if they were
84 >18 and < 80 years old and had initially confirmed SARS-CoV-2 infection by quantitative
85 RT-PCR on nasal swabs or bronchoalveolar lavage. Patients were excluded if they were
86 known to have prior chronic respiratory insufficiency, if they had a significant psychiatric
87 pathology, or if they had a life expectancy estimated at less than one year. The protocol
88 was approved by the ethics committee (Comité de Protection des Personnes (CPP)
89 Grand-Est Ref 21 04 11) and written informed consent was obtained from all patients at
90 the time of enrollment.

91 The study consisted of a follow-up at 3, 6 and 12 months after symptom onset
92 (NCT04519320). From 149 patients that were initially admitted to intensive care with a
93 diagnosis of SARS-CoV-2, a total of 85 patients were included in the cohort study (suppl
94 Figure). Seventy-three patients (86%) completed the 12 months visit. A clinical evaluation,
95 lung function tests, chest computed tomography (CT) and CPET were carried out on the
96 same day. A total of 64 patients performed CPET (2 patients declined to perform CPET, 2
97 had no negative RT-PCR control for SARS-CoV-2 and 6 had contraindications for
98 performing CPET (pericardial effusion, acid-base disorders, orthopedic pathology and
99 recent head trauma)). Four patients were excluded from the final analysis, 3 because of
100 submaximal efforts and 1 patient that had presented severe arrhythmia during the test
101 leading to an early exercise termination.

102

103

104 ***Pulmonary function tests***

105 Pulmonary function tests were realized in all the patients and included spirometry,
106 measurement of lung volumes by plethysmography and single-breath determination of
107 diffusion capacity of the lung for carbon monoxide (D_{LCO}) (Platinum Elite, MGC Diagnostic
108 Corporation). Predicted normal values were derived from the reference values in
109 accordance with current recommendations [7, 8]. The modified Medical Research Council
110 (mMRC) dyspnea scale (0 to 4) was used to rate chronic dyspnea [9]. Participants were
111 categorized as having dyspnea ($mMRC \geq 1$) or not ($mMRC = 0$).

112 ***CT image acquisition and analysis***

113 Chest CT scans were acquired in the supine position at full inspiration without
114 contrast medium (Revolution CT; GE Healthcare, Milwaukee, WI, USA). CT images were
115 assessed by two readers blinded to clinical data that evaluated the presence and extent of
116 ground-glass opacities (GGOs), reticulations, bronchiectasis, emphysema and
117 honeycombing as defined by the glossary of terms of the Fleischner Society [10].

118 ***Cardiopulmonary exercise test***

119 Symptom-limited incremental CPET was performed according to the ERS
120 guidelines on an electronically braked cycle ergometer (Ergometrics 900; Ergoline; Bitz,
121 Germany) [11].

122 After a steady-state resting period, a 3 min warm-up was conducted at about 20%
123 of individually estimated maximal workload. A progressive increase in workload was then
124 applied every minute (10 to 20 W/min) depending on the patient's physical condition,
125 medical history and according to a total exercise time between 8 and 12 minutes. Tests

126 were terminated at the point of symptom limitation (peak exercise) or in the presence of
127 electrocardiographic changes. Subjects rated the magnitude of their perceived breathing
128 and leg discomfort by pointing to a number on the 10-point Borg scale [12]. Oxygen
129 saturation with pulse oximetry, heart rate (HR) and 12-lead electrocardiogram (ECG) and
130 non-invasive blood pressure measurements were monitored throughout exercise.

131 Breath-by-breath gas exchange values were measured using a Masterscreen CPX
132 metabolic cart (MGC-CPX System; MGC Diagnostics Corporation) and were expressed as
133 30 s averages, according to recommended guidelines. Minute ventilation ($V'E$), oxygen
134 uptake ($V'O_2$), carbon dioxide production ($V'CO_2$), end-tidal partial pressure of carbon
135 dioxide ($P_{et}CO_2$), tidal volume (V_t) and breathing rate were recorded. Oxygen pulse
136 ($V'O_2$ /heart rate), ventilatory equivalent for oxygen uptake ($V'E/V'O_2$) and ventilatory
137 equivalent for carbon dioxide production ($V'E/V'CO_2$) were calculated. The respiratory
138 exchange ratio (RER) was defined as $V'CO_2/V'O_2$. The anaerobic threshold (AT) was
139 determined by both ventilatory equivalents and V-slope methods. $V'E/V'CO_2$ slope was
140 calculated from rest to peak exercise.

141 Blood samples were drawn from the arterialized earlobe and measurements of
142 partial pressure of oxygen (PaO_2) and carbon dioxide (CO_2) were performed at rest, at
143 anaerobic threshold (AT) and at peak exercise. Lactatemia was determined at rest, at AT,
144 at maximal exercise and 5 min of recovery time. Breathing reserve (BR) % was calculated
145 as $BR = (\text{predicted maximum voluntary minute ventilation [MMV]} - \text{peak VE})/\text{MMV} \times 100$,
146 with predicted MMV = $FEV_1 \times 40$. Peak heart rate (HR) was expressed as a percentage of
147 maximum predicted HR, calculated as $HR_{max} = 210 - (0.65 \times \text{age})$. Physiological dead
148 space (VD/V_t) was calculated according to Bohr's equation corrected for the additional
149 instrument dead space: $VD/V_t = (PaCO_2 - P_{et}CO_2 \text{ mean})/PaCO_2 - (VD [\text{machine}]/V_t)$.

150 Tests were considered maximal if a plateau of the $V'O_2 > 60$ seconds was obtained
151 (variation of $V'O_2 < 150$ mL between 2 increments), RER > 1.1 , a perceived exertion > 7 on

152 the Borg scale, peak HR > 100% of predicted, breathing reserve <15% and/or important
153 metabolic acidosis.

154 Normal predicted values for $V'O_2$ were calculated according to the reference
155 equation of Wassermann [13]. A reduced peak exercise capacity was defined by a peak
156 $V'O_2$ < 85% of predicted [4].

157 ***Statistical analyses***

158 Statistical analysis was performed using GraphPad Prism version 9.0 (GraphPad
159 Software Inc., San Diego, CA, USA). Normal distribution of quantitative variables was
160 tested by the Kolmogorov-Smirnov test. Descriptive statistics are presented as mean \pm
161 standard deviation (SD), median (25th to 75th percentile), or number (%), as appropriate.
162 Student's T or Mann–Whitney U-test tests were computed to assess statistical differences
163 between groups for normal or non-normal quantitative variables, respectively. Categorical
164 variables were analyzed by Fisher's exact test when appropriate. Correlations were
165 examined by Spearman rank test or Pearson test. Multiple linear regression was applied
166 for peak $V'O_2$ (ml/kg/min) as dependent variable, using a stepwise approach of potential
167 determinants that showed significant associations in previous univariate analysis. Age, sex
168 and body mass index (BMI) were included in the final multivariable model. The reported p
169 values were two-sided, with a significance level set at $p < 0.05$.

170

171

172

173

174

175

176 **Results**

177 ***Baseline characteristics of the study population***

178 The demographics, comorbidities and ICU treatments of patients at inclusion are
179 summarized in Table 1. The mean age was 64.6 years (\pm 9.6), 78% were male. All
180 patients were initially admitted in an intensive care unit (ICU) and were treated according
181 to local standards at that time. The majority of the patients fulfilled criteria for initial ARDS
182 according to the Berlin definition [14], 90% were intubated, 45% received steroids and
183 more than 90% received early anticoagulant therapy. A pulmonary embolism was
184 diagnosed in 27% of the patients during their stay. Peak values during ICU stay for main
185 blood laboratory findings are shown in Table 1. All patients included in the study had early
186 rehabilitation during their hospital stay. More than half of the patients (65%) were further
187 referred to a pulmonary rehabilitation center and most of the other patients had regular
188 home physiotherapy sessions after their hospital discharge.

189 ***Characteristics of the study population at 12 months follow-up***

190 The clinical, pulmonary function tests and imaging characteristics of the patients at
191 12 months follow-up are summarized in Table 2. Persistent dyspnea was reported by half
192 of the patients (50%) (mMRC scale \geq 1). Only a minority of patients had functional
193 pulmonary impairment at rest. Two patients showed a mild restrictive ventilatory pattern,
194 and 4 patients had airflow obstruction, three of them had a previous diagnosis of COPD.
195 Mildly impaired DLCO, defined as Z-score DLCO $<$ -1.64, was present in 6 patients (10%),
196 4 were already diagnosed with COPD before SARS-CoV2 infection. High resolution
197 computed tomography (HRCT) of the chest showed pulmonary abnormalities in 50

198 patients (84%). Cardiac evaluation at rest was only proposed to patients that had
199 presented pulmonary embolism during their hospital stay. In these patients, transthoracic
200 echocardiography was within normal limits with no signs of pulmonary hypertension.

201 ***Cardiopulmonary exercise test (CPET) results at 12 months follow-up***

202 Adequate exercise test efforts were obtained in all the patients analyzed. Table 3
203 summarizes the main exercise parameters of the study cohort at the anaerobic threshold
204 (AT) and at peak. Most of the patients had an adequate $V'O_2$ at AT (median predicted
205 64.8% [57.2-70.9]). The median peak predicted $V'O_2$ was 98 % [87.2-106.3] (mean peak
206 $V'O_2$ 21.7 \pm 5.2 mL/min/Kg). Reasons for stopping exercise were leg discomfort in 55% of
207 patients, breathing discomfort in 36.6% patients and both in 5% patients.

208 Circulatory parameters revealed a mean peak predicted oxygen pulse at 103.7 % (\pm
209 19.9). Only 8 patients had a mildly decreased O_2 pulse, 3 of them were under
210 betablockers. The mean peak predicted heart rate was 96.6 % (\pm 12.7), and the median
211 HR/ $V'O_2$ slope was in the limit of normal at 41.9 (33.6-48.7).

212 Mean respiratory equivalents at peak were slightly elevated compared to expected
213 values ($V'E/V'O_2$ ratio at 42.7 [\pm 6.6] and $V'E/V'CO_2$ ratio at 37.5 [34-42]) and the mean
214 $V'E/V'CO_2$ slope from rest to peak was also slightly skewed to increased values compared
215 to expected values (37.2 \pm 6.7) [15]. There was also a trend to a widened median alveolar-
216 arterial O_2 pressure difference at peak (35.2 mmHg [31.2-44.8]).

217 **Predictors of peak oxygen uptake**

218 We next examined the relationship between peak $V'O_2$ (ml/min/kg) and variables of
219 interests. Univariate analysis revealed that peak $V'O_2$ was strongly correlated to the 6-
220 minute walk test (MWT) distance recorded at 12 months (Figure 1a). As expected,
221 absolute values of lung function test parameters at 12 months (FEV_1 , VC and D_{LCO}) were
222 significantly associated to peak $V'O_2$ (suppl Table 1).

223 Among variables recorded during the management of the acute COVID-19
224 infection, length of ICU stay showed the most significant correlation with peak $V'O_2$ (Figure
225 1b). Simplified acute physiology score (SAPS II) and length of curarization had a weaker
226 correlation with peak $V'O_2$ (suppl Table 1).

227 In a multiple linear regression analysis, the length of ICU stay remained an
228 independent predictor of $V'O_2$ and combined to age, sex, and BMI explained 57% of the
229 variance of $V'O_2$ peak at 12 months (Table 4).

230 **Comparison of patients with reduced and normal exercise capacity**

231 Twelve patients (20%) had reduced peak exercise capacity ($V'O_2$ <85% of
232 predicted) (Table 5). The median peak predicted $V'O_2$ (82% [73.9-83.9]) and workload
233 (85.7 % [80.1-96.9]) were only mildly decreased. When compared to patient with
234 preserved peak exercise capacity, patients with reduced capacity had a significantly higher
235 BMI (33.4 ± 6.2 vs 30.1 ± 4.5 , $p=0.04$) and a significantly longer ICU stay (29.7 ± 13.1 vs
236 19.1 ± 11.3 $p=0.006$). No significant differences were observed between both groups
237 regarding age, other prior comorbidities, pulmonary embolism during ICU stay and
238 respiratory rehabilitation. No significant differences were observed for CT scan
239 abnormalities. However, patients with a reduced exercise capacity had a significantly lower
240 % predicted FEV1 (97.4 ± 16.9 vs 110.8 ± 19.7 ; $p=0.03$), FVC (97.5 ± 17.8 vs $110.8 \pm$
241 16.9 , $p=0.01$) and a lower % predicted D_{LCO} (91.3 (65.6-98.1) vs 103 (92.3-114.2);
242 $p=0.01$). Assessment of each individual with limited peak exercise capacity revealed that
243 the primary limitation was ventilatory limitation in 6 patients (50%). Among patients with
244 ventilatory impairment, 5 of them were former smokers and had prior COPD and/or lung
245 emphysema on chest CT. Physical deconditioning was observed for the 6 (50%) others
246 patients.

247 In the group of patients having an exercise capacity considered within normal limits,

248 the median peak predicted $V'O_2$ was 101.6 % [94.8-107.5] (mean of 23.0 ml/kg/min [\pm 4.7])
249 (Table 5). The main reasons for termination were leg discomfort in 52.1% of patients and
250 dyspnea in 37.5%. Despite having a normal exercise capacity, it was worth noting that
251 patients had increased mean ventilatory equivalents for CO_2 with a mean peak $V'E/V'CO_2$
252 at 37.5 (34-41) and a mean $V'E/V'CO_2$ slope from rest to peak at 37.2 [\pm 6.6]. The median
253 median alveolar-arterial O_2 pressure difference at peak appeared also widened (34.7
254 mmHg [31.7-43.9]).

255 **Ventilatory efficiency parameters in patients with normal exercise capacity**

256 As we observed that a majority of patients with normal exercise capacity showed
257 elevated mean ventilatory equivalents for CO_2 during exercise, we next focused on the
258 evolution of ventilatory efficiency parameters in this group.

259 It was worth noting that at AT, 18 of those 48 patients (37.5%) had a $V'E/V'CO_2$
260 ratio > 35 and 7 patients (14.6%) had even a $V'E/V'CO_2$ ratio > 40. At peak exercise,
261 56.2% (n=27) of patients had a $V'E/V'CO_2$ slope > 35 and 41.7% (n=20) had a $V'E/V'CO_2$
262 slope > 40. Anarchical evolution of tidal volume was not observed. In contrast, elevated
263 ventilatory equivalents for CO_2 were associated with abnormal dead space ventilation.
264 Indeed, an abnormal increase of the physiological dead space from AT to peak was
265 observed in 68.1% (n=32) of the patients with a median VD/Vt of 0.27 (0.21-0.32) at AT
266 and 0.29 (0.25-0.34) at peak (Figure 2a). Moreover, the median peak alveolar-arterial
267 gradient for O_2 was abnormally elevated (35.2 mmHg [31.2-44.8]) with 48.9 % of patients
268 (n=23) having a $P(A-a) \geq 35$ mmHg (Figure 2b). $PetCO_2$ at peak was significantly lower in
269 subjects with an abnormal increase of VD/Vt ($p=0.001$) (Figure 2c).

270 Univariate analysis revealed that dead space at peak (VD/Vt) was associated with
271 parameters related to pulmonary exchange capacity at rest (pulmonary diffusing capacity)
272 and during exercise ($V'E/V'CO_2$ ratio and slope, $PetCO_2$, pO_2 and alveolar-arterial gradient
273 (Table 6). Notably, dead space at peak was positively correlated to D-Dimer plasma

274 concentration from blood samples collected during ICU stay. Reanalysis after excluding
275 patients with pulmonary embolism during ICU stay did not alter this correlation.

276 Interestingly, patients with persistent dyspnea (n=23) had a significantly higher
277 mean peak dead space (0.32 ± 0.07 vs 0.28 ± 0.06 ; $p=0.04$) and a higher widening of their
278 mean peak alveolar-arterial gradient (40.9 ± 9.8 vs 34.2 ± 5.9 ; $p=0.006$) (Supl Table 2).
279 There was no significant difference for the mean peak VE/VCO₂ ratio and the mean
280 VE/VCO₂ slope. Performance and circulatory parameters during exercise were also similar
281 between both groups. As expected, breathlessness was the predominant symptom that
282 resulted in test termination in patients with persistent dyspnea. Patients with persistent
283 dyspnea were slightly older. No differences were observed for any other parameters
284 recorded during initial hospitalization including the presence of pulmonary embolism
285 between patients with and without persistent dyspnea. Lung function at rest was also
286 similar at 12 months between both groups (Supl Table 2).

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305 **Discussion**

306 This prospective study assessed cardiopulmonary exercise performance in 60
307 patients, 12 months after a critical COVID-19 infection during the first wave that required
308 initial ICU management. The patients of our cohort presented well-established risk factors
309 for severe COVID-19 such as advanced age, a predominance of male sex and a high BMI
310 [16]. As expected, hypertension and dyslipidemia were the most frequent chronic
311 comorbidities.

312 Despite the severity of the initial clinical presentation, exercise capacity assessed
313 by CPET were within normal limits in most of the patients 12 months after the acute
314 infection. Impairment was predominantly related to persistent deconditioning or prior
315 respiratory co-morbidities. These results confirm previous studies assessing exercise
316 capacity by CPET 3 to 6 months after hospital release and reporting that remaining
317 exercise limitation after COVID-19 is primarily related to physical deconditioning rather
318 than to physiological impairment [5, 6, 17, 18]. Thus, recovery of physical capacities after a
319 critical COVID-19 infection appears better than in patients with other ARDS etiologies [19,
320 20].

321 In our study, 12 months after the acute infection, the length of ICU stay was still an
322 independent predictor of peak $V'O_2$, including the patients that had recovered a peak $V'O_2$
323 considered within normal limits. Even if other studies have already reported associations

324 between length of ICU stay after COVID-19 and peak $V'O_2$ [21, 22], we were surprised that
325 this association remained still true several months after hospital release. This was even
326 more unexpected as all our patients had received early physiotherapy management in the
327 acute hospital setting followed by either inpatient rehabilitation or extensive physiotherapy
328 for several weeks at home for most of them.

329 Another intriguing observation in our study was that many patients having a peak
330 $V'O_2$ within normal limits and normal rest lung function, showed ventilatory inefficiency
331 during exercise, with increased $V'E/V'CO_2$ ratios at AT and at peak associated with an
332 increased $V'E/V'CO_2$ slope. Ventilatory inefficiency after acute COVID-19 has already
333 been reported but mainly attributed to dysfunctional breathing with inappropriate
334 hyperventilation suggestive of post-traumatic syndrome [23]. In contrast to our study, these
335 studies enrolled predominantly patients having had mild COVID-19 [21, 24-26].

336 In our patients, there was no evidence of exaggerated hyperventilatory response.
337 Indeed, we did not see abnormal respiratory alkalosis, nor anarchical evolution of tidal
338 volume. However, ventilatory inefficiency was associated in our study with increased
339 physiological dead space ventilation. Indeed, we observed that nearly two-thirds of the
340 patients with a normal peak predicted $V'O_2$ exhibited an increase of the VD/Vt ratio
341 between AT and peak exercise. Ventilatory inefficiency without hyperventilation syndrome
342 has been suggested by other groups but these studies included patients with a range of
343 disease severity combining data from outpatients, hospitalized patients, and those who
344 had required admission to the ICU [22, 27]. Of interest, Ambrosino *et al.* identified in a
345 study that included mostly severe-to-critical COVID-19 patients without any prior history of
346 cardiovascular or pulmonary disease shortly after hospital release, higher VE/VCO_2 ratios
347 and VE/VCO_2 slopes and a lower VD/Vt decrease among patients with reduced exercise
348 capacity [28].

349 In healthy individuals, VD/Vt decreases usually during exercise as Vt increases

350 several folds and to a much greater extent than the small increase in VD [29]. An increase
351 of the physiological dead space ventilation during exercise is usually considered as
352 abnormal and may suggest the presence of several cardiac and pulmonary disorders.
353 However, increasing VD/VT during exercise is mostly sensitive for pulmonary vascular
354 disease [30-32]. As in our study the majority of patients with normal exercise capacity had
355 normal rest pulmonary function and no cardiovascular abnormalities, the increase of
356 physiological dead space ventilation associated to a low peak PetCO₂ may point to
357 pulmonary vascular disease.

358 It is now apparent that SARS-CoV-2 infection induces endothelial cell dysfunction
359 with systemic inflammatory response resulting in a prothrombotic state manifesting
360 especially with microthrombosis [1]. Notably, in our study, peak VD/Vt values at 12
361 months were positively correlated to peak D-Dimers plasma concentrations from blood
362 samples collected during ICU stay. D-Dimers are a strong biomarker for hypercoagulability
363 and thrombotic events and can be linked to endothelial dysfunction reported during acute
364 COVID-19 [33, 34]. Therefore, the observed ventilatory inefficiency in our patients may
365 point to infra-clinical pulmonary vasculopathy sequelae due to lung micro-thrombotic
366 events during acute SARS-CoV-2 infection. In a study aiming to quantify endothelial
367 alterations in 23 patients with moderate to critical COVID-19, sublingual video microscopy
368 confirmed microcirculatory alterations that were closely associated with D-Dimer levels
369 [35]. More recently, in a cohort of severe-to-critical COVID-19 patients, Ambrosino *et al.*
370 showed that persistent endothelial dysfunction explored by ultrasound assessment of
371 endothelium-dependent flow-mediated dilation (FMD) was correlated to ventilatory
372 inefficiency parameters during CPET in a subgroup of patients [28].

373 Half of our patients, including those who had an exercise capacity within normal
374 limits, still complained of persistent dyspnea. A recent study evaluating the health-related
375 quality of life and persistent symptoms in critically ill COVID-19 patients at twelve months

376 identified a similar proportion with 58.4% of patients with persistent mild dyspnea that was
377 weakly correlated with both DLCO and length of invasive mechanical ventilation [36]. In
378 our study, we found no clear association between dyspnea, length of ICU stay, effort
379 capacity or rest lung function parameters. However, patients with persistent dyspnea had
380 significantly higher mean peak dead space associated to a higher widening of their mean
381 peak alveolar-arterial gradient during exercise.

382 Some potential limitations of our study should be noted. Our study was conducted
383 in a single center. There was also a missing baseline assessment of cardiopulmonary
384 function at rest before SARS-CoV-2 infection in our patients. Even if nearly all the patients
385 with normal exercise capacity and ventilatory inefficiency at exercise had spirometry and
386 predicted DLCO within normal limits, it would have been interesting to compare the results
387 with matched controls. Indeed, more than half of our study cohort were smokers or former
388 smokers. Moreover, we were not able to measure the diffusing capacities of the lung for
389 nitric oxide (NO) which combined to D_{LCO} would have been useful to evaluate more
390 precisely the pulmonary vascular implication. Finally, all patients of our cohort were treated
391 according to local standards at the time of the first wave of COVID-19. Consequently, only
392 45% of them received corticosteroids but notably all of the patients were precociously
393 anticoagulated during their ICU stay.

394

395

396

397

398

399

400

401

402

403

404

405

406

407 **Conclusion**

408 In the current study we report that 12 months after critical COVID-19 most of the
409 patients had a peak $V'O_2$ considered within normal limits. The length of the ICU stay
410 remained a significant predictor of peak $V'O_2$ and therefore prolonged cardiopulmonary
411 rehabilitation and exercise activity should be encouraged in this population. Notably, more
412 than half of the patients who had a normal exercise capacity were still complaining of
413 persistent dyspnea and two-thirds showed abnormal ventilatory efficiency during exercise
414 suggestive of pulmonary vasculopathy. These findings may raise the question of a
415 prolonged antithrombotic therapy in the management of critical post-COVID-19. Further
416 studies, based on invasive hemodynamic measurements during exercise are required to
417 clarify our observations.

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435 **Table 1.** Baseline characteristics of the study population.

	<i>n</i> = 60
Age (years)	64.6 ± 9.6
Male	47 (78%)
BMI (kg/m ²)	30.7 ± 5
Smoking status	
Active smoker	1 (1.7%)
Former smoker	33 (55%)
Never smoker	26 (43.3%)
Comorbidities before SARS-CoV-2 infection	
Obesity (BMI > 30)	33 (55%)
Cardiovascular	
Ischemic heart disease	5 (8.3%)
Hypertension	28 (46.7%)
Dyslipidemia	21 (35%)
Diabetes	15 (25%)
Respiratory diseases	
COPD	5 (8.3%)
Asthma	6 (10%)
Sleep apnea	12 (20%)

Thromboembolic disease	
Deep vein thrombosis	3 (5%)
Pulmonary embolism	0 (0.0%)
Initial hospital management	
Intensive care unit	
Length of ICU stay (days)	21.2 ± 12.4
ARDS	54 (90 %)
Endotracheal intubation with mechanical ventilation	54 (90 %)
Neuromuscular blocking agents	53 (89.8%)*
High-dose steroids	27 (45%)
Anticoagulant therapy	55 (91.7%)
Prone position	47 (79.7%)*
Pulmonary embolism	16 (26.7%)
DDimers (ng/ml)	2760 (1601-4507)**
Fibrinogen (g/L)	5.06 ± 1.16
Creatinine (mg/dl)	87.0 (71-117)
CRP (mg/ml)	199.8 ± 94.6
Total WBC count (10 ⁹ /L)	5.4 ± 1.3
Pulmonology unit stay (days)	48.9 ± 36.5
Total length of stay (days)	68.1 ± 45.5
Rehabilitation center	39 (65%)
Home care physiotherapy	9 (15%)

436 Values are expressed as number of subjects (%), means ± SD or medians [first quartile; third
437 quartile]. Abbreviations: BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary disease;
438 ICU, Intensive Care Unit; £ARDS, Acute Respiratory Distress Syndrome, in accordance to the
439 Berlin definition criteria; CRP, C-Reactive Protein; WBC, White Blood Cell. *Data was unavailable
440 for n=1 patient.** Data was unavailable for n=6 patients.

441

442 **Table 2.** Characteristics of the study population at 12 months follow-up.

	n = 60
Respiratory symptoms	
Dyspnea	
mMRC 0	30 (50%)
mMRC ≥ 1	30 (50%)
Cough	9 (15%)
Pulmonary function tests	
VC (L)	3.7 (3.1-4.3)
VC (% predicted)	109 (95.8-120.5)
FEV ₁ (L)	3.03 (2.5-3.5)
FEV ₁ (% predicted)	106.3 (94.5-123.5)
FEV ₁ /VC (%)	81 (72.2-85)
TLC (L)	5.99 (5.1-6.6)
TLC (% predicted)	93 (85.2-103.5)
D _{LCO} cor (ml/min/mmHg)	23.8 (19.7-27.1)
D _{LCO} cor (% predicted)	99.1 (90.5-112.9)
KCO (ml/min/mmHg/L)	4.4 (9.9-4.8)
KCO (% predicted)	103 (94.3-114.9)
pO ₂ (mmHg)	82.2 ± 9.2
pCO ₂ (mmHg)	36.8 ± 3.9
Bicarbonate (mmol/L)	23.3 ± 2.1
Chest Computed tomography scan	
Normal	10 (16 %)
Reticulations	
1-25%	34 (57%)
26-50%	8 (13%)
>50%	0 (0.0%)
Ground-glass opacities	
1-25%	27 (45%)
26-50%	1 (1.7%)
>50%	1 (1.7%)
Bronchiectasis	
1-25%	33 (55%)
26-50%	2 (3.3%)
>50%	0 (0.0%)
Emphysema	

1-25%	5 (8.3%)
26-50%	3 (5.0%)
>50%	3 (5.0%)
Honeycombing	
1-25%	3 (5.0%)
>25%	0 (0.0%)

443 Data are shown as the number of subjects (%), means \pm SD (standard deviation) or medians [first
444 quartile; third quartile]. Abbreviations: mMRC, modified Medical Research Council; FVC, Forced
445 Vital Capacity; FEV1, Forced Expiratory Volume at 1st second; TLC, Total Lung Capacity; D_{LCOcor} ,
446 Diffusion Capacity of carbon monoxide; KCO, Carbon monoxide transfer coefficient; PcapO₂,
447 capillary arterialized pO₂; PcapCO₂, capillary arterialized pCO₂.

448

449

450 **Table 3.** Cardiopulmonary exercise test (CPET) results at 12 months follow-up (n=60).

Variables	Anaerobic threshold	Peak
Reasons for stopping		
Leg discomfort	-	33 (55%)
Breathing discomfort	-	22 (36.6%)
Both	-	3 (5%)
Other	-	2 (3.3%)
Performance		
Workload (W, % predicted)	65.8 (57.5-73.2)	103 (92.5-121.3)
V'O ₂ (L/min)	1.3 ± 0.3	1.9 ± 0.5
V'O ₂ (L/min, % predicted)	65 (57.1-70.9)	98.2 (87.2-106.2)
V'O ₂ (ml/min/kg)	14.2 ± 3.1	21.8 ± 5.2
V'O ₂ , (ml/min/kg, % predicted)	64.8 (57.2-70.9)	98.0 (87.2-106.3)
V'O ₂ /Watts (ml/min/watts)	15.3 (14-16.5)	14.3 (13.5-15.7)
MET	4.1 ± 0.9	6.2 ± 1.5
RER	0.9 ± 0.1	1.1 ± 0.1
Ventilation		
VT (L)	7.7 ± 0.4	2.2 ± 0.5
VT (% FVC)	46.2 ± 10.9	59.8 ± 8.2
VE (L/min)	39.7 ± 9.7	81.9 ± 22
RR (breaths/min)	24 ± 5	37 ± 6
Breathing reserve (%)	66.7 ± 8.7	32.6 ± 13.7
PetCO ₂ (mmHg)	39.6 ± 5.7*	34.3 ± 5.2*
Circulation		
HR (beats/min, % predicted)	78.2 ± 11.2	96.6 ± 12.7
Heart Rate reserve (%)	24.3 (12.8-29.9)	2.3 (0-15)
V'O ₂ pulse (ml/beat/min)	10.5 ± 2.6	12.9 ± 3.1
V'O ₂ pulse (% predicted)	84.6 ± 16.1	103.7 ± 19.9
ΔHR/ΔV'O ₂	-	41.9 (33.6-48.7)
ΔV'O ₂ /ΔWR	-	14.2 (13.5-15.7)
Gas exchange		
V'E/V'O ₂	31.7 ± 4.9	42.7 ± 6.6
V'E/V'CO ₂	33.5 (30-37)	37.5 (34-42)
V'E/V'CO ₂ slope	-	37.2 ± 6.7*
OUES (L/min)	-	1.8 (1.6-2.3)*
pH	7.4 ± 0.03*	7.3 ± 0.05*
pCapO ₂ (mmHg)	82.3 (73.4-85.4)*	85.4 (72.4-87)*

pCapCO ₂ (mmHg)	38.2 ± 4.1*	34.8 ± 4.1*
P(A-a)O ₂ (mmHg)	26.4 (22.4-34.9)*	35.2 (31.2-44.8)*
V _D /V _T	0.27 (0.21-0.34)**	0.29 (0.25-0.35)**
Metabolic		
Lactatemia (mmol/L)	3.4 ± 1.1*	7.6 ± 2.2**

451 Data are shown as the number of subjects (%), means ± SD or medians [first quartile; third
452 quartile]. Abbreviations: V'O₂, oxygen uptake; MET, metabolic equivalent; ; RER, Respiratory
453 Exchange Ratio; VT, tidal volume; FVC, Forced Vital Capacity; VE, minute ventilation; RR,
454 respiratory rate; PetCO₂, end-tidal pressure of CO₂; HR, heart rate; WR: Work Rate; V'E/V'O₂ and
455 V'E/V'CO₂, ventilatory equivalents for oxygen and carbon dioxide; OUES, Oxygen Uptake
456 Efficiency Slope; PcapO₂, capillary arterialized pO₂; PcapCO₂, capillary arterialized pCO₂; P(A-
457 a)O₂ Alveolar-arterial gradient for O₂; VD, dead space. *Missing values for n=3 patients.
458 **Missing values for n=1 patient.

459

460

461 **Table 4.** Multiple linear regression identifying factors associated with $V'O_2$ peak
462 (ml/kg/min).

	p value	β coefficient	95% CI for β	Standard error of β
Intercept	<0.0001	53.60	44.07 to 63.13	4.75
Age (years)	< 0.001	-0.19	-0.23 to -0.08	0.05
Sexe	< 0.001	-4.36	-6.85 to -1.90	1.23
BMI	< 0.001	-0.42	-0.65 to -0.19	1.11
Length of ICU stay (days)	0.01	-0.10	-0.18 to -0.02	0.04
R² 0.57				

463

464

465

466

467
468

Table 5. Comparison of patients with reduced and normal exercise capacity.

Variables	VO2 peak < 85% (n=12)	VO2 peak ≥ 85% (n=48)	p value
Patient's characteristics			
Age (years)	65.4 (59.8-72.3)	68.1 (58.1-71.8)	0.96
BMI (kg/m ²)	33.4 ± 6.2	30.1 ± 4.5	0.04
Smoker or former smoker	8 (66.7%)	26 (54.2%)	0.52
ICU stay (days)	29.7 ± 13.1	19.1 ± 11.3	0.006
Ischemic heart disease	1 (8.3%)	4 (8.3%)	>0.99
COPD	1 (8.3%)	4 (8.3%)	>0.99
Asthma	2 (16.7%)	4 (8.3%)	0.59
Pulmonary embolism	3 (25%)	13 (27.1%)	0.88
Respiratory rehabilitation	9 (75%)	30 (62.5%)	0.41
Chest computed tomography scan #			
Emphysema	4 (33.3%)	7 (14.6%)	0.69
Reticulations	9 (75%)	33 (68.7%)	>0.99
Traction bronchiectasis	8 (66.7%)	27 (56.2%)	0.74
Honeycombing	0 (0.0%)	3 (6.2%)	>0.99
Ground-glass opacities	4 (33.3%)	25 (52.1%)	0.24
Pulmonary function tests			
FEV1 (% predicted)	97.4 ± 16.9	110.8 ± 19.7	0.03
FVC (% predicted)	97.5 ± 17.8	110.8 ± 16.9	0.01
TLC (%predicted)	87.7 ± 12.6	95.9 ± 14.3	0.07
DL _{CO} cor (%predicted)	91.3 (65.6-98.1)	103 (92.3-114.2)	0.01
KCO (%predicted)	96.1 ± 29.9	104.8 ± 15.5	0.16
CPET at AT			
PetCO ₂ (mmHg)	39.3 ± 6.9 *	39.6 ± 5.5 **	0.87
Anaerobic threshold (%VO ₂ peak predicted)	59.1 (49.1-65.2)	66.1 (58.1-73.2)	0.01
CPET at peak Performance			
Reasons for stopping exercise			
Leg discomfort	8 (66.7%)	25 (52.1%)	0.51
Dyspnea discomfort	4 (33.3%)	18 (37.5%)	>0.99
Both	0 (0.0%)	3 (6.2%)	>0.99
Others	0 (0.0%)	2 (4.2%)	>0.99

Effort duration (sec)	547.6 ± 128.9	585.7 ± 86.2	0.21
Workload (% predicted)	85.7 (80.1-96.9)	107.2 (98.4-124.5)	<0.0001
V'O ₂ (L/min)	1.6 ± 0.5	2.0 ± 0.5	0.03
V'O ₂ (L/min, % predicted)	82.1 (73.7-83.7)	101.9 (94.6-107.7)	<0.0001
V'O ₂ (ml/min/kg)	16.9 ± 4.2	23.0 ± 4.7	0.0001
V'O ₂ (ml/min/kg, % predicted)	82 (73.9-83.9)	101.6 (94.8-107.5)	<0.0001
MET	4.8 ± 1.2	6.6 ± 1.3	0.0001
Ventilation			
VE (L/min)	74.9 ± 21.9	83.6 ± 21.9	0.22
RER	1.1 ± 0.1	1.1 ± 0.1	0.14
Breathing reserve (%)	34.4 ± 15.4	32.1 ± 13.4	0.61
PetCO ₂ (mmHg)	34.0 ± 5.3 *	34.3 ± 5.3 **	0.86
Circulation			
HR (beats/min, %predicted)	94.3 ± 11.9	97.2 ± 12.9	0.49
Heart rate reserve (%)	4.1 (0-18.6)	1.6 (0-14.7)	0.68
VO ₂ pulse (%predicted)	83.9 ± 11.3	108.7 ± 18.6	<0.0001
ΔHR/ΔV'O ₂	47.5 (36.6-51.2)	39.9 (32.2-47.5)	0.08
ΔV'O ₂ /ΔWR	13.9 (12.9-16.1)	14.3 (13.6-15.3)	0.54
Gas exchange			
VE/VO ₂ ratio	45.7 ± 7.9	42.1 ± 6.1	0.08
OUES (L/min)	1.6 (1.5-2.0)	1.9 (1.7-2.3)	0.14
VE/VCO ₂ ratio	39.5 (33.5-47.0)	37.5 (34-41)	0.36
VE/VCO ₂ slope	37.2 ± 7.6*	37.2 ± 6.6*	0.99
VD/Vt	0.35 (0.28-0.40)*	0.29 (0.25-0.34)**	0.06
pH	7.3 ± 0.04**	7.3 ± 0.05	0.36
pCapO ₂ (mmHg)	78.2 (54.2-82.1)*	83.8 (76.8-87.1)**	0.05
pCapCO ₂ (mmHg)	35.9 (33.4-39.4)**	34.7 (30.7-37.3)	0.14
P(A-a) (mmHg)	43.49 (29.7-60.5)*	34.7 (31.7-43.9)**	0.23
Metabolic			
Lactatemia (mmol/L)	7.2 ± 2.4*	7.7 ± 2.2	0.54

469 Data are shown as the number of subjects (%), means ± SD or medians [first quartile; third
470 quartile], Student's t- or Mann–Whitney tests were computed to assess statistical differences for
471 normal or non-normal quantitative. Fisher's exact test was used for analysis of contingency tables.
472 Abbreviations: BMI, Body Mass Index; ICU, Intensive Care Unit; COPD: Chronic Obstructive
473 Pulmonary Disease; FEV1, Forced Expiratory Volume at 1st second; FVC, Forced Vital Capacity;
474 TLC, total lung capacity; DLCOcor, lung transfer for carbon monoxide; KCO, carbon monoxide

475 transfer coefficient; $\dot{V}'O_2$, oxygen uptake; MET, metabolic equivalent; RR, respiratory rate; $\dot{V}'E$,
476 minute ventilation; RER, respiratory exchange ratio; $P_{et}CO_2$, end-tidal pressure of CO_2 ; HR, heart
477 rate; WR: Work Rate; $\dot{V}'CO_2$, carbon dioxide production; OUES, oxygen uptake efficiency slope;
478 $\dot{V}'E/\dot{V}'O_2$ and $\dot{V}'E/\dot{V}'CO_2$, ventilatory equivalents for oxygen and carbon dioxide; V_D , dead space;
479 V_t , tidal volume; $P_{cap}O_2$, capillary arterialized pO_2 ; $P_{cap}CO_2$, capillary arterialized pCO_2 ; $P(A-$
480 $a)O_2$; Alveolar-arterial gradient for O_2 . * Missing values for n=2 patients. **Missing values for n=1
481 patient.

482

483 **Table 6.** Results of univariate analysis to identify factors associated with peak VD/Vt in
 484 patients with normal exercise capacity (n=48).

	r^2	p value
Patient's characteristics		
Age (years)	0.13	0.01
Sexe	0.07	0.07
BMI (kg/m ²)	0.03	0.2
Length of ICU stay (days)	0.24	0.10
Pulmonary embolism	0.01	0.3
CRP (mg/ml)	0.004	0.6
Fibrinogen (g/L)	0.009	0.5
D-Dimers (ng/ml)	0.12	0.02
Creatinine (mg/dl)	0.07	0.07
Total WBC count (10 ⁹ /L)	0.03	0.2
Pulmonary function tests		
FEV1 (% predicted)	0.08	0.05
FEV1 (L)	0.02	0.3
VC (% predicted)	0.03	0.2
VC (L)	0.002	0.7
DL _{CO} cor (%predicted)	0.15	0.01
DL _{CO} cor (ml/min/mmHg)	0.06	0.09
CPET at AT		
PetCO ₂	-0.53	0.0001
%VO ₂ peak predicted	-0.11	0.46
CPET at peak		
V'O ₂ peak, ml/kg/min %predicted	-0.17	0.25
V'O ₂ peak, ml/kg/min		
PetCO ₂	-0.43	0.003
V'E/VO ₂ ratio	0.48	0.0006
V'E/V'CO ₂ ratio	0.58	<0.0001
V'E/V'CO ₂ slope	0.53	0.0001
V'O ₂ pulse (%predicted)	0.1	0.52
pO ₂ (mmHg)	0.13	0.01
pCO ₂ (mmHg)	0.004	0.8
P(A-a) (mmHg)	0.46	0.01

485 Abbreviations: BMI, Body Mass Index; ICU, Intensive Care Unit; CRP, C-Reactive Protein; WBC,
 486 White Blood Cell; FEV1, Forced Expiratory Volume at 1st second; FVC, Forced Vital Capacity;
 487 TLC, total lung capacity; DL_{CO}cor, lung transfer for carbon monoxide; KCO, carbon monoxide

488 transfer coefficient; $P_{et}CO_2$, end-tidal pressure of CO_2 ; RER, respiratory exchange ratio; $V'O_2$,
489 oxygen uptake; $V'E/V'O_2$ and $V'E/V'CO_2$, ventilatory equivalents for oxygen and carbon dioxide;
490 HR, heart rate; $P_{cap}O_2$, capillary arterialized pO_2 ; $P_{cap}CO_2$, capillary arterialized pCO_2 ; $P(A-a)O_2$
491 Alveolar-arterial O_2 gradient.

492

493 **Figure Legends**

494

495 **Figure 1.** Scatterplot depicting the relationship of peak oxygen uptake ($V'O_2$) with a) 6-
496 minute walk test (MWT) distance b) length of ICU stay (days).

497 **Figure 2.** Evolution of ventilatory efficiency parameters from rest to peak in patients with
498 normal exercise capacity (n=48). a) VD/V_t b) alveolar-arterial gradient c) PetCO


499 **Suppl Figure.** Flowchart of the prospective cohort study.

500 **References**

- 501 1. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. *Nat Rev Microbiol* 2022;
502 20(5): 270-84.
- 503 2. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19:
504 a longitudinal cohort study. *Lancet* 2021; 398(10302): 747-58.
- 505 3. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in
506 Patients After Acute COVID-19. *JAMA* 2020; 324(6): 603-5.
- 507 4. American Thoracic S, American College of Chest P. ATS/ACCP Statement on
508 cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2003; 167(2): 211-77.
- 509 5. Rinaldo RF, Mondoni M, Parazzini EM, et al. Deconditioning as main mechanism of
510 impaired exercise response in COVID-19 survivors. *Eur Respir J* 2021; 58(2).
- 511 6. Skjorten I, Ankerstjerne OAW, Trebinjac D, et al. Cardiopulmonary exercise
512 capacity and limitations 3 months after COVID-19 hospitalisation. *Eur Respir J* 2021;
513 58(2).
- 514 7. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for
515 spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J*
516 2012; 40(6): 1324-43.
- 517 8. Stanojevic S, Graham BL, Cooper BG, et al. Official ERS technical standards:
518 Global Lung Function Initiative reference values for the carbon monoxide transfer factor for
519 Caucasians. *Eur Respir J* 2017; 50(3).
- 520 9. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory
521 symptoms and the diagnosis of chronic bronchitis in a working population. *Br Med J* 1959;
522 2(5147): 257-66.
- 523 10. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner
524 Society: glossary of terms for thoracic imaging. *Radiology* 2008; 246(3): 697-722.
- 525 11. Force ERST, Palange P, Ward SA, et al. Recommendations on the use of exercise
526 testing in clinical practice. *Eur Respir J* 2007; 29(1): 185-209.
- 527 12. Borg G. Ratings of perceived exertion and heart rates during short-term cycle
528 exercise and their use in a new cycling strength test. *Int J Sports Med* 1982; 3(3): 153-8.
- 529 13. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing.
530 *Am Rev Respir Dis* 1984; 129(2 Pt 2): S49-55.
- 531 14. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome:
532 the Berlin Definition. *JAMA* 2012; 307(23): 2526-33.
- 533 15. Sun XG, Hansen JE, Garatachea N, Storer TW, Wasserman K. Ventilatory
534 efficiency during exercise in healthy subjects. *Am J Respir Crit Care Med* 2002; 166(11):

- 535 1443-8.
- 536 16. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
537 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the
538 New York City Area. *JAMA* 2020; 323(20): 2052-9.
- 539 17. Clavario P, De Marzo V, Lotti R, et al. Cardiopulmonary exercise testing in COVID-
540 19 patients at 3 months follow-up. *Int J Cardiol* 2021; 340: 113-8.
- 541 18. Ribeiro Baptista B, d'Humieres T, Schlemmer F, et al. Identification of factors
542 impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-
543 up of prospective COVulnerability cohort. *Respir Res* 2022; 23(1): 68.
- 544 19. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the
545 acute respiratory distress syndrome. *N Engl J Med* 2003; 348(8): 683-93.
- 546 20. Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors
547 of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus
548 outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. *J*
549 *Rehabil Med* 2020; 52(5): jrm00063.
- 550 21. Motiejunaite J, Balagny P, Arnoult F, et al. Hyperventilation: A Possible Explanation
551 for Long-Lasting Exercise Intolerance in Mild COVID-19 Survivors? *Front Physiol* 2020;
552 11: 614590.
- 553 22. Debeaumont D, Boujibar F, Ferrand-Devouge E, et al. Cardiopulmonary Exercise
554 Testing to Assess Persistent Symptoms at 6 Months in People With COVID-19 Who
555 Survived Hospitalization: A Pilot Study. *Phys Ther* 2021; 101(6).
- 556 23. Naeije R, Caravita S. Phenotyping long COVID. *Eur Respir J* 2021; 58(2).
- 557 24. Baratto C, Caravita S, Faini A, et al. Impact of COVID-19 on exercise
558 pathophysiology: a combined cardiopulmonary and echocardiographic exercise study. *J*
559 *Appl Physiol (1985)* 2021; 130(5): 1470-8.
- 560 25. Taverne J, Salvator H, Leboulch C, et al. High incidence of hyperventilation
561 syndrome after COVID-19. *J Thorac Dis* 2021; 13(6): 3918-22.
- 562 26. Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP, Natelson BH. Use of
563 Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus
564 Disease. *JACC Heart Fail* 2021; 9(12): 927-37.
- 565 27. Fresard I, Genecand L, Altarelli M, et al. Dysfunctional breathing diagnosed by
566 cardiopulmonary exercise testing in 'long COVID' patients with persistent dyspnoea. *BMJ*
567 *Open Respir Res* 2022; 9(1).
- 568 28. Ambrosino P, Parrella P, Formisano R, et al. Cardiopulmonary Exercise
569 Performance and Endothelial Function in Convalescent COVID-19 Patients. *J Clin Med*

- 570 2022; 11(5).
- 571 29. Robertson HT, Pellegrino R, Pini D, et al. Exercise response after rapid intravenous
572 infusion of saline in healthy humans. *J Appl Physiol* (1985) 2004; 97(2): 697-703.
- 573 30. Dantzker DR, D'Alonzo GE. Pulmonary gas exchange and exercise performance in
574 pulmonary hypertension. *Chest* 1985; 88(4 Suppl): 255S-7S.
- 575 31. Gille T, Laveneziana P. Cardiopulmonary exercise testing in interstitial lung
576 diseases and the value of ventilatory efficiency. *Eur Respir Rev* 2021; 30(162).
- 577 32. Weatherald J, Philipenko B, Montani D, Laveneziana P. Ventilatory efficiency in
578 pulmonary vascular diseases. *Eur Respir Rev* 2021; 30(161).
- 579 33. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future
580 prospects. *Blood* 2009; 113(13): 2878-87.
- 581 34. Bonaventura A, Vecchie A, Dagna L, et al. Endothelial dysfunction and
582 immunothrombosis as key pathogenic mechanisms in COVID-19. *Nat Rev Immunol* 2021;
583 21(5): 319-29.
- 584 35. Rovas A, Osiaevi I, Buscher K, et al. Microvascular dysfunction in COVID-19: the
585 MYSTIC study. *Angiogenesis* 2021; 24(1): 145-57.
- 586 36. Gamberini L, Mazzoli CA, Prediletto I, et al. Health-related quality of life profiles,
587 trajectories, persistent symptoms and pulmonary function one year after ICU discharge in
588 invasively ventilated COVID-19 patients, a prospective follow-up study. *Respir Med* 2021;
589 189: 106665.

a**b**